Recent Updates
Recently added Catalysts
SNDX Positive Sentiment Score: 65/100

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Friday, April 4, 2025 1 min read
Key Takeaway: Syndax Pharmaceuticals announced inducement grants for four new employees to purchase up to 50,000 shares of common stock under its 2023 Inducement Plan. The stock options are structured to vest over a four-year period, promoting long-term commitment among new hires. The company continues to develop its innovative pipeline of cancer therapies, including two FDA-approved products. This initiative reflects Syndax's focus on growth and enhancing its workforce.

Market Sentiment Analysis

POSITIVE FACTORS

  • The inducement grants signal confidence in the company's growth and employee retention.
  • Syndax is actively expanding its workforce, which may enhance its operational capabilities.
  • The pipeline includes FDA-approved therapies, indicating regulatory validation of its products.

Full Press Release Details

NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Pharmaceuticals, Inc.

Frequently Asked Questions

What recent inducement awards did Syndax Pharmaceuticals announce?

On April 1, 2025, Syndax granted inducement awards for 50,000 shares to four new employees.

How will the stock options at Syndax vest?

The options will vest over four years, with 25% vesting after one year and monthly thereafter.

What therapies is Syndax Pharmaceuticals developing?

Syndax's pipeline includes Revuforj® and Niktimvo™, both FDA-approved cancer therapies.

What is the focus of Syndax Pharmaceuticals?

Syndax aims to innovate cancer care through its diverse pipeline and ongoing clinical trials.

Where can I find more information about Syndax Pharmaceuticals?

More details are available on their website and social media platforms.

Tags: SNDX Viatris Investor Conferences Healthcare Syndax inducement grants cancer therapies FDA-approved
Last updated: Apr 4, 2025